Mylan N.V. (NASDAQ:MYL) was the target of a significant increase in short interest in the month of September. As of September 29th, there was short interest totalling 28,385,090 shares, an increase of 7.0% from the September 15th total of 26,525,497 shares. Based on an average daily volume of 5,866,326 shares, the days-to-cover ratio is presently 4.8 days. Currently, 5.6% of the company’s stock are short sold.

Mylan N.V. (NASDAQ MYL) opened at 38.29 on Thursday. The company has a market cap of $20.53 billion, a P/E ratio of 30.95 and a beta of 1.30. The company’s 50-day moving average is $32.74 and its 200-day moving average is $36.35. Mylan N.V. has a 12 month low of $29.39 and a 12 month high of $45.87.

Mylan N.V. (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.08). Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. The business had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3 billion. During the same quarter in the previous year, the firm posted $1.16 earnings per share. The business’s revenue was up 15.7% on a year-over-year basis. On average, equities research analysts expect that Mylan N.V. will post $4.58 EPS for the current fiscal year.

Several research analysts have recently issued reports on MYL shares. Cowen and Company reiterated a “hold” rating and issued a $30.00 target price (down previously from $43.00) on shares of Mylan N.V. in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $32.00 target price (down previously from $33.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. Citigroup Inc. upgraded shares of Mylan N.V. from a “neutral” rating to a “buy” rating and upped their target price for the stock from $36.00 to $42.00 in a research note on Wednesday, August 16th. Wells Fargo & Company set a $32.00 target price on shares of Mylan N.V. and gave the stock a “hold” rating in a research note on Wednesday, October 4th. Finally, Cantor Fitzgerald set a $34.00 target price on shares of Mylan N.V. and gave the stock a “hold” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $41.21.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bellwether Investment Group LLC lifted its stake in Mylan N.V. by 0.3% during the 2nd quarter. Bellwether Investment Group LLC now owns 6,622 shares of the company’s stock valued at $257,000 after acquiring an additional 23 shares during the period. Suntrust Banks Inc. lifted its stake in Mylan N.V. by 0.7% during the 2nd quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after acquiring an additional 60 shares during the period. Cleararc Capital Inc. lifted its stake in Mylan N.V. by 0.6% during the 1st quarter. Cleararc Capital Inc. now owns 10,394 shares of the company’s stock valued at $405,000 after acquiring an additional 67 shares during the period. Dai Ichi Life Insurance Company Ltd lifted its stake in Mylan N.V. by 0.4% during the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock valued at $1,009,000 after acquiring an additional 107 shares during the period. Finally, Sei Investments Co. lifted its stake in Mylan N.V. by 1.0% during the 1st quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock valued at $541,000 after acquiring an additional 134 shares during the period. Institutional investors and hedge funds own 71.97% of the company’s stock.

WARNING: This article was reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/12/mylan-n-v-myl-short-interest-up-7-0-in-september.html.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.